阻断程序性死亡受体-1通路拮抗剂研究进展  

Progress on Antagonists Blocking PD-1 Pathway

作　　者：夏黎明 岳锋[2,3] 祝仰钊 张秋雨 王选年 XIA Li-ming;YUE Feng;ZHU Yang-zhao;ZHANG Qiu-yu;WANG Xuan-nian(College of Animal Science and Technology,Henan University of Science and Technology,Luoyang,Henan,471000,China;School of Biotechnology,Xinxiang University,Xinxiang,Henan,453003,China;Key Laboratory of Zoonotic Diseases in Xinxiang City,Xinxiang,Henan,453003,China;College of Veterinary Medicine,Henan Agricultural University,Zhengzhou,Henan,450046,China)

机构地区：[1]河南科技大学动物科技学院,河南洛阳471000 [2]新乡学院生物工程学院,河南新乡453003 [3]新乡市人兽共患病学重点实验室,河南新乡453003 [4]河南农业大学动物医学学院,河南郑州450046

出　　处：《动物医学进展》2025年第3期103-107,共5页Progress In Veterinary Medicine

基　　金：国家自然科学基金项目(31702216);河南省高等学校青年骨干教师培养计划项目(2020GGJS249)。

摘　　要：程序性死亡受体-1(programmed death-1,PD-1)是一种免疫抑制性受体,通过与表现于特定淋巴细胞表面的PD-L1配体结合,触发淋巴细胞死亡,进而抑制免疫反应。在某些慢性病毒感染及肿瘤等疾病的进程中,PD-1及其配体的表达量及转录水平显著升高,这导致免疫系统中T细胞的激活受阻,免疫功能随之受损。探索干预PD-1通路的目的是恢复T细胞的活性。论文梳理了近年来关于PD-1/PD-L1通路的研究进展,特别是单克隆抗体类拮抗剂、小分子肽类拮抗剂及小分子非肽类抑制剂等领域的最新发现,为免疫联合治疗提供新的策略和方法,旨在逆转动物和人体内的免疫抑制状态,开拓联合免疫治疗的新前景。PD-1 is an immunosuppressive receptor that induces lymphocyte death by binding with its ligand PD-L1,displayed on certain lymphocytes'surfaces,thereby suppressing the immune response.Extensive research in recent years has revealed that in conditions such as chronic viral infections and cancers,there is a significant increase in the expression and transcription levels of PD-1 and its ligand.This results in the inhibition of T cell activation and subsequent impairment of immune function.Given these findings,researchers have begun to explore strategies to intervene in the PD-1 pathway with the aim of restoring T cell activity and enhancing immune responses.This review compiles recent advances in research on the PD-1/PD-L1 pathway,with a particular focus on monoclonal antibodies as antagonists,small-molecule peptide antagonists,and small-molecule non-peptide inhibitors.These discoveries offer new strategies and methods for combination immune therapy aimed at reversing immune suppression in both animals and humans,paving new avenues for immune therapeutic treatments.

关 键 词：程序性死亡受体-1 拮抗剂 免疫功能损伤 免疫联合治疗 

分 类 号：S852.4[农业科学—基础兽医学]